Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

A Bristol Myers Squibb immunotherapy currently approved ... Participants were dosed with the study drug, Opdualag, in combination with Nivolumab, a different BMS immunotherapy that’s already ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...